X4 Pharmaceuticals has signed a License and Supply Agreement with Norgine Pharma, granting Norgine exclusive rights to distribute and sell X4's product mavorixafor in several regions, with an upfront payment of $28.5 million and potential milestone payments of up to $226 million, plus royalties on sales.